To OTC Journal Members:
 

Astralis/Hercules Development (OTC BB: HDVG) Announces Negotiations With European Pharmaceutical Co.

News today from Astralis confirms our original suspicions that Astralis would be seeking major value added partners for both capital and technology expertise to help move the company forward.

The company announced it has entered into advanced negotiations with a European based Pharmaceutical company for a strategic investment. According to the press release "If successful in completing the transaction, Astralis anticipates a significant infusion of capital into the Company".

If you missed our original profile on this company, now would be a good time to review it. Click Here to be taken directly to the original profile. For individual investors in the microcap arena, this company is one of the most exciting situations we have ever seen, and we believe all risk oriented investors should own some stock in this company.

We have already covered most of the risk factors associated with investing in Hercules Development at this time. They include the following:

• The merger has not been completed. The purchase of shares of Hercules is not Astralis yet. According to both parties, the transaction should close by the end of October. If it becomes derailed you stand to lose a substantial portion of your investment.
• The editors of the OTC Journal do not have the technical expertise to evaluate the merits of this revolutionary new drug. We have not been to Caracas, Venezuela to interview treated patients or the Venezuelan FDA which has already approved the drug.
• It is anticipated the FDA approval process could take five to six years.
• As it stands today, the company does not have the anticipated required capital to take this drug through the FDA Approval Process.

Pharmaceutical companies have the expertise to evaluate the technology. If a major pharmaceutical company were to make a significant investment, this would confirm the upside potential of this drug and mitigate risks associated with both the lack of capital and the need for technological help.

We advised investors to start with 25% to 50% of the risk capital they planned to set aside for this exciting company. Today's news release helps mitigate some of the risk associated with this investment, and therefore it would be appropriate to add to your current position on this news. However, the closing of a major financing with a pharmaceutical company would trigger our belief that you should be 100% invested.

Today the stock closed $.38 below our original entry price of $3.66. If you invested on the first day, today's price provides the opportunity to lower your average cost. If you don't own this stock yet, you should invest if you have any risk capital available. This company has exciting upside potential, and every risk oriented investor should participate. We expect the stock will trade at much higher levels if and when a final deal is announced with a Pharmaceutical company but there are no guarantees.

Here is the complete text of the press release for your review:
 

SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts! 

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today! 
 

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $100,000 in cash and 100,000 options exercisable at $2.50 by the Investor Relations Group for publishing information on Astralis LLC for a period of one year. Fifty thousand options are exercisable immediately, and fifty thousand become eligible on April 1, 2002. Please review our policy on selling shares found within our Mission Statement at our home page.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.